MAOB and Cognitive impairment: In a multicenter, randomized, placebo-controlled phase II trial, Schifitto et al. evaluated the safety, tolerability, and efficacy of the selegiline transdermal system (STS), a skin patch formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline, in individuals with HIV-associated cognitive impairment [135].